Bristol-Myers Squibb unveils pipeline at investors meeting

Share this article:
Bristol-Myers Squibb is on track to submitting three regulatory submissions for three internally discovered compounds by the end of the year, it said during an overview meeting with investors this week.
The company's New Drug Application for its investigational hepatitis B treatment, entecavir, has already been accepted for priority review by the FDA. An NDA for muraglitazar, the first in a new class
of compounds to fight diabetes, and a Biologics License Application for abatacept, an investigational treatment
for rheumatoid arthritis, are expected to be submitted by the end
of 2004.
BMS also highlighted six additional compounds in development
including:
•LEA29Y, an in-house discovered investigational biologic that has
shown promise in solid organ transplant rejection in Phase II studies
•Edifoligide which is in Phase II development and is being investigated for the prevention of vein graft failure in coronary and peripheral bypass graft surgery.
•Ixabepilone, a novel epothilone analog in Phase II development to
treat certain cancers.
•Vinfluine, a Phase III cancer compound being co-developed with
Pierre Fabre Medicament S.A.
•MDX-010, a monoclonal antibody being investigated as a latestage
anti-cancer treatment
•Src/ABL Kinase Inhibitor, an internally discovered, multitargeted
investigational compound and being investigated in chronic myelogenous leukemia.
Share this article:

Email Newsletters

More in Business Briefs

Miss Idaho shows off diabetes pump

NPR reports that the move has made Sierra Sandison a type 1 diabetes hero and that users have given the Facebook photo over 4,000 "likes."

Roche is hungry, not starving for M&A

CEO Severin Schwan tells Reuters that the Swiss firm will be looking for small acquisitions and partnerships.

AbbVie nabs Shire for $54B

AbbVie, in the latest example of a US drugmaker seeking to lower its tax rate, said today that it's buying Dublin-based Shire for $54 billion.